QCG
CTSO icon

Quadrant Capital Group’s Cytosorbents Corp CTSO Stock Holding History

Quadrant Capital Group’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-482
Closed -$1K – 2666
2022
Q2 		$1K Buy
+482
New +$1.11K ﹤0.01% 2347

Other funds holding CTSO

SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Quadrant Capital Group's CTSO Position: Q3 2022 in Review

Quadrant Capital Group sold out of Cytosorbents Corp (CTSO) in Q3 2022, closing a stake of 482 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in CTSO in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 60 funds tracked by Wall St. Rank hold CTSO as of Q3 2022.

  • Quadrant Capital Group reported no remaining Cytosorbents Corp position as of Q3 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 482 Cytosorbents Corp shares in Q3 2022, an estimated $1K.
  • Quadrant Capital Group first reported a position in Cytosorbents Corp in Q2 2022 and held it in 1 quarter.
  • Quadrant Capital Group's Cytosorbents Corp position peaked at $1K in Q2 2022.
  • 60 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2022.

Based on Quadrant Capital Group's 13F filing for Q3 2022, filed 10 Nov 2022.